<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; OSI Pharmaceuticals Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/osi-pharmaceuticals-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ABT) Pharma &amp; Biotech Stock Review &#8211; April 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/04/29/abt-pharma-biotech-stock-review-april-2010-industry-outlook/35472</link>
		<comments>http://www.stockbloghub.com/2010/04/29/abt-pharma-biotech-stock-review-april-2010-industry-outlook/35472#comments</comments>
		<pubDate>Thu, 29 Apr 2010 14:10:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MIL]]></category>
		<category><![CDATA[Millipore Corporation]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[OSI Pharmaceuticals Inc]]></category>
		<category><![CDATA[OSIP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=35472</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/29/abt-pharma-biotech-stock-review-april-2010-industry-outlook/35472/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OSIP) OSI Pharmaceutical&#8217;s Drug Tarceva Gets FDA Approval for Lung Cancer</title>
		<link>http://www.stockbloghub.com/2010/04/19/osip-osi-pharmaceuticals-drug-tarceva-gets-fda-approval-for-lung-cancer/34256</link>
		<comments>http://www.stockbloghub.com/2010/04/19/osip-osi-pharmaceuticals-drug-tarceva-gets-fda-approval-for-lung-cancer/34256#comments</comments>
		<pubDate>Mon, 19 Apr 2010 21:03:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[OSI Pharmaceuticals Inc]]></category>
		<category><![CDATA[OSIP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=34256</guid>
		<description><![CDATA[Recently, OSI Pharmaceuticals (OSIP) received approval from the US Food and Drug Administration (FDA) for its lead product, Tarceva (erlotinib) as a maintenance therapy for patients suffering from non-small-cell lung cancer (NSCLC), whose disease has not worsened after multiple rounds of chemotherapy. The drug has been co-developed with Genentech, a part of Roche Holdings (RHHBY). Earlier, in March 2010, the European Committee for Medicinal Products for Human Use (CHMP) recommended the approval of Tarceva for the first-line maintenance of patients suffering from locally advanced or metastatic NSCLC. A final decision is expected shortly. The FDA approval was based on the late-stage SATURN (front-line maintenance therapy in NSCLC post-chemotherapy non-progressors) study. The international, placebo-controlled, randomized, double-blinded, study conducted by Roche enrolled 889 advanced NSCLC patients across approximately 160 sites worldwide. The ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/19/osip-osi-pharmaceuticals-drug-tarceva-gets-fda-approval-for-lung-cancer/34256/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OSIP) OSI Pharmaceuticals Earns Good News on Tarceva</title>
		<link>http://www.stockbloghub.com/2010/03/27/osip-osi-pharmaceuticals-earns-good-news-on-tarceva/31457</link>
		<comments>http://www.stockbloghub.com/2010/03/27/osip-osi-pharmaceuticals-earns-good-news-on-tarceva/31457#comments</comments>
		<pubDate>Sat, 27 Mar 2010 21:43:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[OSI Pharmaceuticals Inc]]></category>
		<category><![CDATA[OSIP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31457</guid>
		<description><![CDATA[Recently, a European advisory committee recommended the approval of Tarceva (erlotinib) as a maintenance therapy for patients suffering from lung cancer following multiple rounds of chemotherapy. Tarceva is the lead drug of OSI Pharmaceuticals Inc. (OSIP). Tarceva has been co-developed with Genentech, which is now a part of Roche Holdings (RHHBY). The European Committee for Medicinal Products for Human Use (CHMP) recommended the approval of Tarceva for the first-line maintenance of patients suffering from locally advanced or metastatic non-small-cell lung cancer (NSCLC). The European Commission is expected to give its decision on the matter within 45 days. The favorable recommendation from the European advisory committee was based on the late-stage SATURN (front-line maintenance therapy in NSCLC post-chemotherapy non-progressors) study. The international, placebo-controlled, randomized, double-blinded, study conducted by Roche enrolled 889 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/27/osip-osi-pharmaceuticals-earns-good-news-on-tarceva/31457/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OSIP) OSI Pharmaceuticals Gets Tarceva Review Extension from FDA</title>
		<link>http://www.stockbloghub.com/2010/01/18/osip-osi-pharmaceuticals-gets-tarceva-review-extension-from-fda/25192</link>
		<comments>http://www.stockbloghub.com/2010/01/18/osip-osi-pharmaceuticals-gets-tarceva-review-extension-from-fda/25192#comments</comments>
		<pubDate>Tue, 19 Jan 2010 00:36:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[OSI Pharmaceuticals Inc]]></category>
		<category><![CDATA[OSIP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25192</guid>
		<description><![CDATA[OSI Pharmaceuticals (OSIP) received a setback recently with the US Food and Drug Administration (FDA) extending the review date of Tarceva (erlotinib), for its use as a first-line maintenance therapy in advanced non-small cell lung cancer (NSCLC) patients. Tarceva, OSIP’s lead product has been developed in collaboration with Genentech, a part of Roche (RHHBY). While the original Prescription Drug User Fee Act (PDUFA) date was January 18, 2010, the FDA has extended it by another 90 days to April 18, 2010. The extension follows the submission of additional data in support of the original application. We were not surprised by the delay as the FDA Oncologic Drugs Advisory Committee (ODAC) voted 12 -1 recommending against the approval of Tarceva for this indication in December 2009. In 2004, the FDA approved ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/18/osip-osi-pharmaceuticals-gets-tarceva-review-extension-from-fda/25192/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OSIP) OSI Pharmaceuticals Narrows 2010 Guidance</title>
		<link>http://www.stockbloghub.com/2009/12/27/osip-osi-pharmaceuticals-narrows-2010-guidance/23527</link>
		<comments>http://www.stockbloghub.com/2009/12/27/osip-osi-pharmaceuticals-narrows-2010-guidance/23527#comments</comments>
		<pubDate>Sun, 27 Dec 2009 23:48:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[OSI Pharmaceuticals Inc]]></category>
		<category><![CDATA[OSIP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23527</guid>
		<description><![CDATA[OSI Pharmaceuticals Inc. (OSIP) recently announced that it has narrowed its 2010 revenue guidance. However, the company still expects earnings to grow at 10% or more. OSI Pharma currently expects 2010 revenue growth rate to be in the mid-teens. On Dec. 3 2009, the company presented the guidance for revenue growth in the high teens over the next several years. On the same day it had reaffirmed 2009 revenue guidance of approximately $425 million. The trimming of the 2010 revenue forecast is primarily attributable to the negative opinion expressed by the advisory panel of the U.S. Food and Drug Administration (FDA) regarding expanding the approval of OSIP’s lead lung cancer drug Tarceva to patients already responding to chemotherapy. The panel voted 12-1 against Tarceva as a follow-up therapy in those ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/27/osip-osi-pharmaceuticals-narrows-2010-guidance/23527/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OSIP) OSI Pharmaceuticals Tarceva Sees Setback</title>
		<link>http://www.stockbloghub.com/2009/12/18/osip-osi-pharmaceuticals-tarceva-sees-setback/23214</link>
		<comments>http://www.stockbloghub.com/2009/12/18/osip-osi-pharmaceuticals-tarceva-sees-setback/23214#comments</comments>
		<pubDate>Sat, 19 Dec 2009 00:08:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[OSI Pharmaceuticals Inc]]></category>
		<category><![CDATA[OSIP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23214</guid>
		<description><![CDATA[Recently, OSI Pharmaceuticals, Inc. (OSIP) announced that the advisory panel of the U.S. Food and Drug Administration (FDA) did not recommend the additional usage of its lung cancer drug Tarceva in patients already responding to chemotherapy. The panel voted 12-1 against using Tarceva as a follow-up therapy in patients who have successfully undergone chemotherapy. The U.S. agency is expected to decide on whether to approve Tarceva for this indication by Jan 18, 2010. The negative recommendation for the OSIP drug was based on a review of the data from the pivotal late-stage SATURN study (front-line maintenance therapy in non-small cell lung cancer (NSCLC) post-chemotherapy non-progressors), which showed a statistically significant improvement in progression-free survival coupled with overall survival with Tarceva compared to placebo in the NSCLC maintenance setting. However, the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/18/osip-osi-pharmaceuticals-tarceva-sees-setback/23214/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENZN) Enzon Beats Expectations &#8211; Announces Sell-off</title>
		<link>http://www.stockbloghub.com/2009/11/11/enzn-enzon-beats-expectations-announces-sell-off/20250</link>
		<comments>http://www.stockbloghub.com/2009/11/11/enzn-enzon-beats-expectations-announces-sell-off/20250#comments</comments>
		<pubDate>Wed, 11 Nov 2009 20:42:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ENZN]]></category>
		<category><![CDATA[Enzon Pharmaceuticals Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[OSI Pharmaceuticals Inc]]></category>
		<category><![CDATA[OSIP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20250</guid>
		<description><![CDATA[Enzon (ENZN) achieved break-even earnings during the third quarter of 2009, better than the Zacks Consensus Estimate of loss of 7 cents but below the year-ago earnings of 1 cent. The company reported revenues of $44.6 million, a decline of 9% compared to $48.8 million reported in the third quarter of 2008. Enzon records revenues from three sources &#8212; products, royalties and contract manufacturing. The three segments recorded a decline of 1%, 6% and 56%, respectively, compared to the year-ago period. Enzon has four marketed products &#8212; Oncaspar for the treatment of acute lymphoblastic leukemia (ALL); DepoCyt for lymphomatous meningitis; Abelcet for antifungal infection related to cancer and Adagen used to treat severe combined immunodeficiency disease (SCID), commonly known as the &#8220;bubble boy&#8221; disease. Apart from Oncaspar, whose sales remained ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/11/enzn-enzon-beats-expectations-announces-sell-off/20250/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OSIP) OSI Pharmaceuticals Inc Easily Beats Estimates</title>
		<link>http://www.stockbloghub.com/2009/10/26/osip-osi-pharmaceuticals-inc-easily-beats-estimates/18680</link>
		<comments>http://www.stockbloghub.com/2009/10/26/osip-osi-pharmaceuticals-inc-easily-beats-estimates/18680#comments</comments>
		<pubDate>Mon, 26 Oct 2009 23:13:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[OSI Pharmaceuticals Inc]]></category>
		<category><![CDATA[OSIP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18680</guid>
		<description><![CDATA[OSI Pharmaceuticals Inc. (OSIP) has reported third-quarter earnings of 81 cents per share, which was way above the Zacks Consensus Estimate of 35 cents. The company had earned 64 cents per share in the year-ago quarter. Total revenues for the quarter came in at $111.45 million as against $94.57 million in the year-ago quarter, reflecting an increase of 17.8%. The company’s top growth driver Tarceva &#8212; OSI&#8217;s marketed product to treat lung and pancreatic cancer &#8212; contributed the lion’s share of the revenues. Revenues related to Tarceva increased 9.9% to $88.74 million from $80.71 million in the year-ago quarter. Tarceva is promoted in the U.S. by both OSI and Genentech &#8212; now a part of the Roche Group (RHHBY) &#8212; where both sales force costs and U.S. profits are split ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/26/osip-osi-pharmaceuticals-inc-easily-beats-estimates/18680/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENZN) Enzon Pharma Announces European Approval for Cimzia</title>
		<link>http://www.stockbloghub.com/2009/10/08/enzn-enzon-pharma-announces-european-approval-for-cimzia/17197</link>
		<comments>http://www.stockbloghub.com/2009/10/08/enzn-enzon-pharma-announces-european-approval-for-cimzia/17197#comments</comments>
		<pubDate>Thu, 08 Oct 2009 19:10:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ENZN]]></category>
		<category><![CDATA[Enzon Pharmaceuticals Inc]]></category>
		<category><![CDATA[OSI Pharmaceuticals Inc]]></category>
		<category><![CDATA[OSIP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Schering-Plough Corporation]]></category>
		<category><![CDATA[SGP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17197</guid>
		<description><![CDATA[Yesterday, Enzon Pharma (ENZN) announced the European Commission approval of UCB’s Cimzia (certolizumab pegol) for the treatment of adult patients with moderate-to-severe active rheumatoid arthritis (RA). Cimzia utilizes Enzon&#8217;s PEGylation technology. Earlier in May 2009, Cimzia received the US Food and Drug Administration&#8217;s (FDA) approval. Apart from RA, the drug is used to treat Crohn’s disease. Cimzia is a PEGylated anti-TNFa &#8211; Tumor Necrosis Factor alpha. Enzon receives royalties from several drugs manufactured using this technology – Schering Plough’s (SGP) Pegintron, Macugen marketed by Pfizer (PFE) and OSI Pharmaceuticals (OSIP) and Roche’s Pegasys. We believe the approval of Cimzia will boost its sales, thereby increasing the royalty income for Enzon. In a positive development, earlier this week, an FDA advisory panel voted in favor of recommending Pegintron as a treatment in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/08/enzn-enzon-pharma-announces-european-approval-for-cimzia/17197/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

